Skip to main content
ATAI
NASDAQ Life Sciences

Director Files Intent to Sell $3 Million in Atai Beckley Stock

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$3.73
Mkt Cap
$1.355B
52W Low
$1.15
52W High
$6.75
52W Position info
224% above low
Off High info
45% below high
Rel. Volume info
2.5× avg
Market data snapshot near publication time

ATAI has more than doubled off its 52-week low of $1.15 on elevated volume (2.5× avg).

Summary

Atai Beckley N.V. Director Cosmo Feilding-Mellen has filed a Form 144 indicating an intent to sell 750,000 shares of common stock, valued at approximately $3 million.


Key Events · Ownership and Investor Activity · ATAI

  • Director Files Intent to Sell

    Cosmo Feilding-Mellen, a Director of Atai Beckley N.V., has filed a Form 144 to sell 750,000 shares of common stock.

  • Significant Value

    The proposed sale has an approximate market value of $3,000,000.00.

  • Shares Acquired via RSU

    The shares were acquired on December 24, 2025, through restricted stock units as equity compensation.


Analysis · ATAI · Life Sciences

This Form 144 filing signals a significant intent to sell by a company director. While the shares were acquired recently through restricted stock units, the proposed sale of $3 million worth of stock represents a notable disposition by an insider. Investors may view this as a potential lack of confidence or a move to diversify holdings, which could exert some downward pressure or create an overhang on the stock.

How filings like this one have moved

In the 30 days to Sep 11, 2026, 30.2% of the 1943 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.21%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ATAI was trading at $3.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $1.15 to $6.75. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ATAI - Latest Insights

ATAI
Sep 08, 2026, 5:09 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $7.32
Real-time Price: $7.35 info
Change: +$0.032 (+0.44%) info
Market Cap: $2.726B info
ATAI
Aug 31, 2026, 4:42 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $7.34
Real-time Price: $7.35 info
Change: +$0.0100 (+0.14%) info
Market Cap: $2.726B info
ATAI
Aug 31, 2026, 4:38 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $7.34
Real-time Price: $7.35 info
Change: +$0.0100 (+0.14%) info
Market Cap: $2.726B info
ATAI
Aug 11, 2026, 4:20 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.25
Real-time Price: $7.35 info
Change: +$0.100 (+1%) info
Market Cap: $2.726B info
ATAI
Aug 10, 2026, 6:09 AM EDT
Filing Type: DEFM14A
Importance Score:
9
Price at Filing: $7.24
Real-time Price: $7.35 info
Change: +$0.110 (+2%) info
Market Cap: $2.726B info